NASDAQ:XBIO

Xenetic Biosciences Q1 2026 Earnings Results & Report

Xenetic Biosciences logo
$1.40 -0.14 (-9.09%)
Closing price 11/20/2026 03:47 PM Eastern
Extended Trading
$1.46 +0.06 (+3.93%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xenetic Biosciences reported Q1 2026 earnings on May 12, 2026. The company reported EPS of -$0.20, while revenue was $806.92 thousand.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Xenetic Biosciences EPS Results

Actual EPS
-$0.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Xenetic Biosciences Revenue Results

Actual Revenue
$806.92 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Xenetic Biosciences Q1 2026 Earnings FAQ

Xenetic Biosciences (NASDAQ:XBIO) reported earnings of -$0.20 per share for Q1 2026. The report was announced on Tuesday, May 12, 2026.

Xenetic Biosciences reported revenue of $806.92 thousand for Q1 2026.

Xenetic Biosciences Earnings Headlines

Contrasting Xenetic Biosciences (XBIO) and Its Peers
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
See More Xenetic Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email.

About Xenetic Biosciences

Xenetic Biosciences (NASDAQ:XBIO) is a biotechnology company focused on developing immuno-oncology treatments. Its XCART platform is designed to create personalized CAR T-cell therapies that recognize tumor-specific antigens on B-cell lymphomas, with the goal of targeting cancer cells while limiting effects on healthy cells.

The company’s earlier work included PolyXen, a drug-delivery platform based on polysialic acid that was designed to extend the time biologic medicines remain in the body. Xenetic’s current stated focus is advancing its XCART technology and related product candidates.

View Xenetic Biosciences Profile